Accent Therapeutics, Inc.

Accent Therapeutics, Inc.

is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts. Founded in 2017, the company focuses on developing small-molecule precision cancer therapies that target critical intracellular dependencies across various cancer types, particularly those with high genomic and chromosomal instability. Accent Therapeutics is dedicated to translating scientific advancements into effective treatments for cancer patients through biomarker-driven medicines. The company is advancing two lead clinical programs, ATX-295 and ATX-559, both in Phase 1/2 trials. ATX-295 targets KIF18A, a protein involved in cell division, while ATX-559 focuses on DHX9, an RNA-modifying protein. Accent Therapeutics has raised $178 million in funding, including a recent $75 million Series C round, and collaborates with major pharmaceutical companies to enhance its research and development efforts. With a team of experienced leaders, Accent Therapeutics aims to address high unmet medical needs in oncology through innovative therapeutic approaches.